Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL.

Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2.

2.

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group.

Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11.

3.

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C.

Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29.

PMID:
30025278
4.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.

Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P.

Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13.

PMID:
30004110
5.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. No abstract available.

PMID:
29740159
6.

"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.

Chapiro E, Lesty C, Gabillaud C, Durot E, Bouzy S, Armand M, Le Garff-Tavernier M, Bougacha N, Struski S, Bidet A, Laharanne E, Barin C, Veronese L, Prié N, Eclache V, Gaillard B, Michaux L, Lefebvre C, Gaillard JB, Terré C, Penther D, Bastard C, Nadal N, Fert-Ferrer S, Auger N, Godon C, Sutton L, Tournilhac O, Susin SA, Nguyen-Khac F; GroupeFrancophone de Cytogénétique Hématologique(GFCH) and the French Innovative Leukemia Organization (FILO) group.

Am J Hematol. 2018 Mar;93(3):375-382. doi: 10.1002/ajh.24990. Epub 2017 Dec 18.

7.

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

PMID:
29112938
8.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

9.

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

Bigenwald C, Harel S, Chevignon F, Roos-Weil D, Bernard OA, Amorim S, Brice P, Adès L, Nloga AM, Sébert M, Braun T, Eclache V, Thieblemont C, Fenaux P.

Br J Haematol. 2018 Jan;180(2):304-308. doi: 10.1111/bjh.14323. Epub 2016 Sep 23. No abstract available.

PMID:
27662562
10.

Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Nguyen-Khac F, Borie C, Callet-Bauchu E, Eclache V, Struski S.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):561-567. Review.

PMID:
27628190
11.

Cytogenetic place in managing myelodysplastic syndromes: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Eclache V, Lafage-Pochitaloff M, Lefebvre C, Penther D, Raynaud S, Tigaud I.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):525-534. Review.

PMID:
27546835
12.

Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Bilhou-Nabéra C, Bidet A, Eclache V, Lippert E, Mozziconacci MJ.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):517-523. Review.

PMID:
27477946
13.

Cytogenetics in the management of hematologic malignancies: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Nguyen-Khac F, Daudignon A, Eclache V, Lafage-Pochitaloff M, Lefebvre C, Luquet I, Penther D.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):509-510. Review.

PMID:
27465598
14.

TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.

Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F.

Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24.

15.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C; GFM (Groupe Francophone des Myelodysplasies).

Am J Hematol. 2015 Aug;90(8):737-8. doi: 10.1002/ajh.24073.

16.

Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients.

Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khalloufi M, Boubaya M, Le Roy C, Varin-Blank N, Delmer A, Levy V, Ajchenbaum-Cymbalista F.

Am J Hematol. 2015 Jan;90(1):E5-8. doi: 10.1002/ajh.23861. Epub 2014 Oct 25.

17.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.

Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.

PMID:
24836762
18.

14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cosson A, Chapiro E, Belhouachi N, Cung HA, Keren B, Damm F, Algrin C, Lefebvre C, Fert-Ferrer S, Luquet I, Gachard N, Mugneret F, Terre C, Collonge-Rame MA, Michaux L, Rafdord-Weiss I, Talmant P, Veronese L, Nadal N, Struski S, Barin C, Helias C, Lafage M, Lippert E, Auger N, Eclache V, Roos-Weil D, Leblond V, Settegrana C, Maloum K, Davi F, Merle-Beral H, Lesty C, Nguyen-Khac F; Groupe Francophone de Cytogénétique Hématologique.

Genes Chromosomes Cancer. 2014 Aug;53(8):657-66. doi: 10.1002/gcc.22176. Epub 2014 Apr 12.

PMID:
24729385
19.

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.

Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C; French ALFA group.

Am J Hematol. 2013 Apr;88(4):306-11. doi: 10.1002/ajh.23403. Epub 2013 Mar 5.

20.

Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblondon V; Groupe Français d'Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW); Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS); Groupe d’Etude des Lymphomes de l’Adulte (GELA).

Haematologica. 2013 Apr;98(4):649-54. doi: 10.3324/haematol.2012.070458. Epub 2012 Oct 12.

21.

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.

Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, Stamatoullas A, Récher C, Prebet T, Moulessehoul S, Fenaux P, Eclache V.

Genes Chromosomes Cancer. 2012 Dec;51(12):1086-92. doi: 10.1002/gcc.21993. Epub 2012 Aug 30.

PMID:
22933333
22.

The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.

Le Roy C, Deglesne PA, Chevallier N, Beitar T, Eclache V, Quettier M, Boubaya M, Letestu R, Lévy V, Ajchenbaum-Cymbalista F, Varin-Blank N.

Blood. 2012 Jul 12;120(2):356-65. doi: 10.1182/blood-2011-12-397158. Epub 2012 May 21.

23.

Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?

Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, Haferlach C, Hildebrandt B, Iqbal AM, Jhanwar SC, Ohyashiki K, Sole F, Vandenberghe P, VanDyke DL, Zhang Y, Dewald GW.

Leuk Res. 2012 Jul;36(7):832-40. doi: 10.1016/j.leukres.2012.03.013. Epub 2012 Apr 25.

PMID:
22537394
24.

Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course.

Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L; BCGHo and the GFCH.

Ann Hematol. 2012 Jun;91(6):863-73. doi: 10.1007/s00277-011-1393-y. Epub 2011 Dec 30.

PMID:
22205151
25.

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.

Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P.

Haematologica. 2012 Feb;97(2):213-8. doi: 10.3324/haematol.2011.045914. Epub 2011 Oct 11.

26.

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.

Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.

Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28.

PMID:
21715006
27.

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.

Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S.

Cell Cycle. 2011 Jul 15;10(14):2323-30. Epub 2011 Jul 15.

PMID:
21654193
28.

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1207-9. doi: 10.1038/leu.2011.63. Epub 2011 Apr 5. No abstract available.

PMID:
21468040
29.

Occurrence of myelodysplastic syndrome in 2 patients with reticular dysgenesis.

Lagresle-Peyrou C, Neven B, Six E, Picard C, Demerens-de Chappedelaine C, Bertrand Y, Jabado N, Chomienne C, Radford-Weiss I, Brouzes C, Asnafi V, MacIntyre E, Donadieu J, Beaupain B, Fenaux P, Eclache V, Fischer A, Cavazzana-Calvo M.

J Allergy Clin Immunol. 2011 Jul;128(1):230-232.e2. doi: 10.1016/j.jaci.2011.02.008. Epub 2011 Mar 31. No abstract available.

PMID:
21458044
30.

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L.

Leuk Res. 2011 Jul;35(7):863-7. doi: 10.1016/j.leukres.2011.02.008. Epub 2011 Mar 10.

PMID:
21396711
31.

Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia.

Nguyen-Khac F, Chapiro E, Lesty C, Grelier A, Luquet I, Radford-Weiss I, Lefebvre C, Fert-Ferrer S, Callet-Bauchu E, Lippert E, Raggueneau V, Michaux L, Barin C, Collonge-Rame MA, Mugneret F, Eclache V, Taviaux S, Dastugue N, Richebourg S, Struski S, Talmant P, Baranger L, Gachard N, Gervais C, Quilichini B, Settegrana C, Maloum K, Davi F, Merle-Béral H.

Am J Blood Res. 2011;1(1):13-21. Epub 2011 Apr 15.

32.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

33.

Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters.

Letestu R, Lévy V, Eclache V, Baran-Marszak F, Vaur D, Naguib D, Schischmanoff O, Katsahian S, Nguyen-Khac F, Davi F, Merle-Béral H, Troussard X, Ajchenbaum-Cymbalista F.

Blood. 2010 Nov 25;116(22):4588-90. doi: 10.1182/blood-2010-06-288274. Epub 2010 Aug 25.

34.

Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™.

Le Roux G, Vlad A, Eclache V, Malanquin C, Collon JF, Gantier M, Schillinger F, Peltier JY, Savin B, Letestu R, Baran-Marszak F, Fenaux P, Ajchenbaum-Cymbalista F.

Int J Lab Hematol. 2010 Dec;32(6 Pt 1):e237-43. doi: 10.1111/j.1751-553X.2010.01247.x.

PMID:
20670338
35.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

36.

Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.

Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA; Groupe Francophone de Cytogénétique Hématologique.

Genes Chromosomes Cancer. 2010 Oct;49(10):919-27. doi: 10.1002/gcc.20802.

PMID:
20629097
37.

Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.

Lippert E, Etienne G, Mozziconacci MJ, Laibe S, Gervais C, Girault S, Gachard N, Tigaud I, Dastugue N, Huguet F, Fort MP, Legros L, Eclache V, Mahon FX.

Haematologica. 2010 Sep;95(9):1604-7. doi: 10.3324/haematol.2009.019109. Epub 2010 Apr 30.

38.

Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.

Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, Nadal N, Taviaux S, Poppe B, Luquet I, Baranger L, Eclache V, Radford I, Barin C, Mozziconacci MJ, Lafage-Pochitaloff M, Antoine-Poirel H, Charrin C, Perot C, Terre C, Brousset P, Dastugue N, Broccardo C.

Blood. 2010 Apr 15;115(15):3089-97. doi: 10.1182/blood-2009-07-234229. Epub 2010 Feb 16.

39.

Detection of chromosomal abnormalities associated with chronic lymphocytic leukemia: what is the best method?

El-Taweel M, Barin C, Cymbalista F, Eclache V.

Cancer Genet Cytogenet. 2009 Nov;195(1):37-42. doi: 10.1016/j.cancergencyto.2009.06.004.

PMID:
19837267
40.

Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.

Adès L, Eclache V, Gardin C, Boehrer S, Leroux G, Martiat P, Fenaux P.

Bone Marrow Transplant. 2010 Apr;45(4):791-2. doi: 10.1038/bmt.2009.225. Epub 2009 Aug 31. No abstract available.

PMID:
19718061
41.

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

Clozel T, Renneville A, Venot M, Gardin C, Kelaidi C, Leroux G, Eclache V, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2009 Oct;94(10):1466-8. doi: 10.3324/haematol.2009.010702. Epub 2009 Jul 16. No abstract available.

42.

miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia?

Cardinaud B, Moreilhon C, Marcet B, Robbe-Sermesant K, LeBrigand K, Mari B, Eclache V, Cymbalista F, Raynaud S, Barbry P.

Leukemia. 2009 Nov;23(11):2174-7. doi: 10.1038/leu.2009.125. Epub 2009 Jun 18. No abstract available.

PMID:
19536169
43.

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

Boehrer S, Adès L, Tajeddine N, Hofmann WK, Kriener S, Bug G, Ottmann OG, Ruthardt M, Galluzzi L, Fouassier C, Tailler M, Olaussen KA, Gardin C, Eclache V, de Botton S, Thepot S, Fenaux P, Kroemer G.

Oncogene. 2009 Jun 4;28(22):2205-18. doi: 10.1038/onc.2009.69. Epub 2009 Apr 27.

PMID:
19398952
44.

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C, Maareck O, Soenen V, Viguié F, Laï JL, Andrieux J, Corm S, Roche-Lestienne C; Fi-LMC Group.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):95-102. doi: 10.1016/j.cancergencyto.2008.01.005.

PMID:
18406870
45.

Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.

Kiladjian JJ, Visentin G, Viey E, Chevret S, Eclache V, Stirnemann J, Bourhis JH, Chouaib S, Fenaux P, Caignard A.

Haematologica. 2008 Mar;93(3):381-9. doi: 10.3324/haematol.11812. Epub 2008 Feb 11.

46.

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.

Eclache V, Da Rocha A, Le Roux G, Fenaux P.

Haematologica. 2008 Feb;93(2):315-6. doi: 10.3324/haematol.11917.

47.

The role of lenalidomide in the management of myelodysplasia with del 5q.

Kelaidi C, Eclache V, Fenaux P.

Br J Haematol. 2008 Feb;140(3):267-78. doi: 10.1111/j.1365-2141.2007.06910.x. Review.

PMID:
18217896
48.

Hyperdiploid karyotypes in acute myeloid leukemia define a novel entity: a study of 38 patients from the Groupe Francophone de Cytogenetique Hematologique (GFCH).

Luquet I, Laï JL, Barin C, Baranger L, Bilhou-Nabera C, Lippert E, Gervais C, Talmant P, Cornillet-Lefebvre P, Perot C, Nadal N, Mozziconacci MJ, Lafage-Pochitaloff M, Eclache V, Mugneret F, Lefebvre C, Herens C, Speleman F, Poirel H, Tigaud I, Cabrol C, Rousselot P, Daliphard S, Imbert M, Garand R, Geneviève F, Berger R, Terre C; Francophone de Cytogenetique Hematologique.

Leukemia. 2008 Jan;22(1):132-7. Epub 2007 Oct 11.

PMID:
17928884
49.

Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?

Lessard M, Hélias C, Struski S, Perrusson N, Uettwiller F, Mozziconacci MJ, Lafage-Pochitaloff M, Dastugue N, Terré C, Brizard F, Cornillet-Lefebvre P, Mugneret F, Barin C, Herry A, Luquet I, Desangles F, Michaux L, Verellen-Dumoulin C, Perrot C, Van den Akker J, Lespinasse J, Eclache V, Berger R; Groupe Francophone de Cytogénétique Hématologique.

Cancer Genet Cytogenet. 2007 Jul 1;176(1):1-21.

PMID:
17574959
50.

Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.

Etienne A, Gelsi-Boyer V, Carbuccia N, Adélaïde J, Barba G, La Starza R, Murati A, Eclache V, Birg F, Birnbaum D, Mozziconacci MJ, Mecucci C, Chaffanet M.

Cancer Genet Cytogenet. 2007 Mar;173(2):154-8.

PMID:
17321332

Supplemental Content

Loading ...
Support Center